Bobby Liaw, MD

Dr. Bobby Liaw looks to the future of metastatic castration-sensitive prostate cancer treatment and provides some advice and clinical pearls.

A key opinion leader reviews how findings from the TITAN study affect treatment of metastatic castration-sensitive prostate cancer.

Bobby Liaw, MD, explains the potential treatment strategy for a prostate cancer case with low-volume metastatic disease.

A prostate cancer expert reviews the treatment approach in the presented case of biochemical recurrence of prostate cancer with high-volume castration-sensitive metastatic disease.

Dr. Bobby Liaw compares the available first-line therapy options for metastatic castration-sensitive prostate cancer and explains how to decide on a therapy.

An oncologist details the first-line therapy options for metastatic castration-sensitive prostate cancer.

Bobby Liaw, MD, presents the case of a 73-year-old man with biochemical recurrence of prostate cancer and metastatic castration-sensitive high-volume disease.